⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EYPT News
EyePoint Pharmaceuticals, Inc. Common Stock
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
globenewswire.com
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
EYPT
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
globenewswire.com
EYPT
Form 8-K
sec.gov
EYPT